公开(公告)号：US20180236024A1

公开(公告)日：2018-08-23

申请号：US15553786

申请日：2016-02-25

Applicant: STC.UNM

Inventor： Vojo P. Deretic ,  Tomonori Kimura

IPC: A61K38/05 ,  A61K45/06 ,  A61K38/17 ,  A61K31/713 ,  A61P1/00 ,  A61P29/00

CPC classification number: A61K38/05 ,  A61K31/713 ,  A61K38/17 ,  A61K45/06 ,  A61P1/00 ,  A61P29/00 ,  A61K2300/00

Abstract: The present invention relates to the discovery that IRGM, encoded by a uniquely human gene which confers risk for inflammatory diseases, affects autoophagy through a hitherto unknown mechanism. The present invention shows that IRGM controls autophagy and that IRGM modulators, in particular, double-stranded RNA, including poly I:C, poly-UG (polyUGUGU) and polyl-CLC and muramyldipeptide and related analogs of same, including N-acetyl muramyl-L-alanyl-D-isoglutamine (DMP) and numerous other compounds as identified herein, which may be used alone, in combination, or in combination with alternative autophagy modulators and additional bioactive agents to provide effective therapies for a number of diseases, including cancer, bacterial infections and inflammatory diseases, especially including tuberculosis infections and Crohn's disease, among others. The present invention is also directed to compositions and methods for treating inflammatory or autophagy-related diseases including diseases which cause excessive inflammation in patients.